{"id":"azd0120-regimen-2","_chembl":{"chemblId":"CHEMBL499175","moleculeType":"Protein","molecularWeight":"828.02"},"_dailymed":null,"_scrapedAt":"2026-03-28T04:57:46.752Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_claudeStub":{"ts":1779123159,"model":"claude-sonnet-4-5-20250929"},"description":"AZD0120 - Regimen 2 is an investigational therapeutic agent being developed by AstraZeneca. Currently in Phase 1 clinical trials, the drug's molecular target, mechanism of action, and specific therapeutic indications have not been publicly disclosed.","indications":{"approved":[{"status":"investigational","condition":null,"patientPopulation":null}]},"trialDetails":[{"nctId":"NCT07295847","phase":"PHASE1","title":"A Study of AZD0120 in Autoimmune Diseases","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2026-01-09","conditions":"Systemic Sclerosis, Idiopathic Inflammatory Myopathies, Rheumatoid Arthritis","enrollment":27},{"nctId":"NCT07224373","phase":"PHASE1","title":"An Open-label Study of AZD0120 in Adults With Multiple Sclerosis","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-12-09","conditions":"Multiple Sclerosis","enrollment":24}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":523,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_1","status":"active","brandName":"AZD0120 - Regimen 2","genericName":"AZD0120 - Regimen 2","companyName":"AstraZeneca","companyId":"astrazeneca","modality":"Biologic","firstApprovalDate":"","aiSummary":"AZD0120 is being studied in clinical trials for Multiple Sclerosis, Systemic Sclerosis, Idiopathic Inflammatory Myopathies, and Rheumatoid Arthritis. AZD0120 - Regimen 2 is one of the interventions being tested in these trials.","enrichmentLevel":2,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}